14 min
How promising is Remdesivir? Coronavirus: The Latest
-
- News Commentary
Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They discuss how useful it is, whether big pharma is solely driven by profit and the prognosis for severe coronavirus sufferers in the second wave.
Read more on the Oxford vaccine: https://bit.ly/2UVfPet |
Read more on Brexit talks: https://bit.ly/36V8f8Y |
Read more on the new quarantine-free list: https://bit.ly/3lMs88H |
For 30 days' free access to The Telegraph: https://www.telegraph.co.uk/audio |
Email: coronaviruspodcast@telegraph.co.uk |
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Hosted on Acast. See acast.com/privacy for more information.
Over a year since the first recorded case of Covid-19 in humans, only one antiviral drug is approved for its treatment. The Telegraph’s Global Health Security team speak to Dr Michael Elliot, Vice President of Medical Affairs at Gilead Sciences, the company that manufactures Remdesivir. They discuss how useful it is, whether big pharma is solely driven by profit and the prognosis for severe coronavirus sufferers in the second wave.
Read more on the Oxford vaccine: https://bit.ly/2UVfPet |
Read more on Brexit talks: https://bit.ly/36V8f8Y |
Read more on the new quarantine-free list: https://bit.ly/3lMs88H |
For 30 days' free access to The Telegraph: https://www.telegraph.co.uk/audio |
Email: coronaviruspodcast@telegraph.co.uk |
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Hosted on Acast. See acast.com/privacy for more information.
14 min